Page last updated: 2024-12-05

tribromoethanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tribromoethanol: major descriptor (66-90); on-line search ETHANOL (66-90); INDEX MEDICUS search TRIBROMOETHANOL (66-90) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6400
CHEMBL ID1697852
CHEBI ID135170
SCHEMBL ID26851
MeSH IDM0173013

Synonyms (65)

Synonym
.beta.-tribromoethanol
2,2-tribromoethanol
ethobrome
nsc2189
narcotyl
tribromethanol
rectanol
2,2-tribromoethyl alcohol
bromethol
tribromoethyl alcohol
75-80-9
ethobrom
ethanol,2,2-tribromo-
avertin
basibrol
narkolan
nsc-2189
tribromoethanol
narcolan
wln: q1xeee
ethanol, 2,2,2-tribromo-
tribromoethanol, 2,2,2-
2,2,2-tribromoethanol
einecs 200-903-1
nsc 2189
brn 1733249
2,2,2-tribromoethyl alcohol
tribromoethanol (van)
avertine
2,2,2-tribromoethanol, 97%
NCGC00166090-01
1329-86-8
CHEBI:135170
T1420
A8483
CHEMBL1697852
2-fluoro-4-chlorobenzenemethylal
S4508
AKOS015964811
tribromoethanol [nf]
149ji83a44 ,
3-01-00-01362 (beilstein handbook reference)
unii-149ji83a44
FT-0609023
tribromoethanol [mi]
tribromoethyl alcohol [mart.]
CCG-213307
SCHEMBL26851
CS-4901
J-640302
.beta.-tribromoethyl alcohol
HY-B1372
AB01563026_01
DTXSID2023698
J-800306
mfcd00004671
Q25105561
AS-13076
HMS3885F06
D87616
SY048840
2,2,2-tribromoethanol;narcolan
2,2,2-tribromoethan-1-ol
EN300-310981
Z1269188950

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Tribromoethanol (400 mg/kg)-treated rats were anesthetized for an average of 10 min, whereas rats that received tribromoethanol (150 mg/kg) and medetomidine (0.5 mg/kg) remained anesthetized for an average of 55 min."( Tribromoethanol-medetomidine combination provides a safe and reversible anesthetic effect in Sprague-Dawley rats.
Bay, TN; Brown, SR; Gopalan, C; Hegade, GM; Talcott, MR, 2005
)
2.49

Toxicity

ExcerptReferenceRelevance
" In the present study, the alpha2-adrenergic agonists xylazine and medetomidine were combined with tribromoethanol to examine their use as alternate and safe anesthetic regimes in rats."( Tribromoethanol-medetomidine combination provides a safe and reversible anesthetic effect in Sprague-Dawley rats.
Bay, TN; Brown, SR; Gopalan, C; Hegade, GM; Talcott, MR, 2005
)
1.99

Dosage Studied

ExcerptRelevanceReference
") 10 min after anesthetic induction, and group 2 received the same dosage at 20 min post-induction."( Tribromoethanol-medetomidine combination provides a safe and reversible anesthetic effect in Sprague-Dawley rats.
Bay, TN; Brown, SR; Gopalan, C; Hegade, GM; Talcott, MR, 2005
)
1.77
"We have established an intraperitoneal dosing regimen for 2,2,2-tribromoethanol-chloral hydrate anesthesia."( Increased anesthesia time using 2,2,2-tribromoethanol-chloral hydrate with low impact on mouse psychoacoustics.
Gow, A; Maheras, KJ, 2013
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organobromine compoundA compound containing at least one carbon-bromine bond.
alcoholA compound in which a hydroxy group, -OH, is attached to a saturated carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase kappa isoform 1Homo sapiens (human)Potency26.67950.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (118)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (36.44)18.7374
1990's13 (11.02)18.2507
2000's32 (27.12)29.6817
2010's27 (22.88)24.3611
2020's3 (2.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.41 (24.57)
Research Supply Index4.81 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index54.90 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.83%)5.53%
Reviews1 (0.83%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other119 (98.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]